Jazz Pharmaceuticals (JAZZ) Equity Income (2016 - 2025)
Jazz Pharmaceuticals (JAZZ) recorded quarterly Equity Income of -$57000.0 in Q4 2025, down 21.28% quarter-over-quarter from -$47000.0 in Q3 2025, and down 256.25% on a YoY basis from $36480.0 in Q4 2024.
Jazz Pharmaceuticals (JAZZ) Equity Income (2016 - 2025) Analysis & Trends
Jazz Pharmaceuticals' Equity Income history runs 10 years deep, the most recent figure standing at -$57000.0 for Q4 2025.
- In Q4 2025, Equity Income fell 256.25% year-over-year to -$57000.0; the TTM figure through Mar 2026 stood at -$190000.0 (up 76.63% YoY), while the FY2025 annual figure was -$732000.0, up 55.9% from the prior year.
- Equity Income was -$57000.0 for Q4 2025 at Jazz Pharmaceuticals, down from -$47000.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of $4.2 million in Q1 2021 to a low of -$4.1 million in Q1 2022.
- Historically, Equity Income has averaged -$799700.0 across 5 years, with a median of -$480500.0 in 2023.
- The sharpest annual moves came in 2021 and 2025: Equity Income soared 2188.46% in 2021, then sank 616.67% in 2025.
- A 5-year view of Equity Income shows it stood at -$3.0 million in 2021, then soared by 74.13% to -$773000.0 in 2022, then soared by 40.36% to -$461000.0 in 2023, then surged by 96.53% to -$16000.0 in 2024, then slumped by 256.25% to -$57000.0 in 2025.
- The last three Equity Income figures came in at -$57000.0 (Q4 2025), -$47000.0 (Q3 2025), and -$86000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Jazz Pharmaceuticals | 13.91 Bn | 12.06 Bn | 934.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57,000.00 |
| Sep 30, 2025 | -47,000.00 |
| Jun 30, 2025 | -86,000.00 |
| Mar 31, 2025 | -500,000.00 |
| Dec 31, 2024 | -16,000.00 |
| Sep 30, 2024 | -285,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | -1.35 Mn |
| Dec 31, 2023 | -461,000.00 |
| Sep 30, 2023 | 126,000.00 |
| Jun 30, 2023 | -1.67 Mn |
| Mar 31, 2023 | -1.01 Mn |
| Dec 31, 2022 | -773,000.00 |
| Sep 30, 2022 | -2.55 Mn |
| Jun 30, 2022 | -2.46 Mn |
| Mar 31, 2022 | -4.14 Mn |
| Dec 31, 2021 | -2.99 Mn |
| Sep 30, 2021 | -3.26 Mn |
| Jun 30, 2021 | 1.37 Mn |
| Mar 31, 2021 | 4.17 Mn |